Wells Fargo’s Cytokinetics CYTK Stock Holding History

Wells Fargo’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100	Closed	-$5.5K	–	7163
2025 Q3	$5.5K	Buy	+100	New	+$4.12K	﹤0.01%	6060

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo's CYTK Position: Q2 2026 in Review

Wells Fargo increased its Cytokinetics (CYTK) stake by 105% in Q2 2026, buying an estimated $5.62M and bringing the position to 152,592 shares worth $13M. The position accounts for ﹤0.01% of the portfolio, ranked #1974.

Wells Fargo first reported a position in CYTK in Q3 2013 and has held it in 52 quarters since. 484 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Wells Fargo held 152,592 shares of Cytokinetics worth $13M as of Q2 2026.
Wells Fargo bought 78,250 Cytokinetics shares in Q2 2026, an estimated $5.62M.
Cytokinetics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #1974 holding.
Wells Fargo first reported a position in Cytokinetics in Q3 2013 and has held it in 52 quarters since.
484 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.